drugset
drugset / Trial / NCT06485843

An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint

NCT06485843 ↗

Phase 2 Recruiting 400 enrolled Ageless Biotech, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study is being conducted to evaluate the safety and tolerability of OA-SYS in patients with moderate to severe OA of the knee joint.

Timeline

Start
2025-05-21
Primary completion
2028-03-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject OA-SYS Cell therapy — Other

Indications

osteoarthritis, knee